Amgen Acquires LENZ Therapeutics for $3.7 Billion
Ticker: LENZ · Form: 8-K · Filed: Apr 15, 2025 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, biotech
Related Tickers: AMGN
TL;DR
Amgen buying LENZ for $3.7B cash, deal expected Q2 2025.
AI Summary
LENZ Therapeutics, Inc. announced on April 15, 2025, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $3.7 billion in cash. This acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This significant acquisition by Amgen Inc. highlights the value of LENZ Therapeutics' pipeline and could lead to new treatment options for patients.
Risk Assessment
Risk Level: low — The filing is a straightforward announcement of a completed acquisition agreement, with no immediate new risks identified.
Key Numbers
- $3.7B — Acquisition Price (Cash amount Amgen is paying for LENZ Therapeutics.)
- Q2 2025 — Expected Closing (Anticipated timeframe for the acquisition to be finalized.)
Key Players & Entities
- LENZ Therapeutics, Inc. (company) — Registrant
- Amgen Inc. (company) — Acquirer
- $3.7 billion (dollar_amount) — Acquisition price
- April 15, 2025 (date) — Date of report
- 201 Lomas Santa Fe Drive, Suite 300 (location) — Principal executive offices
- Solana Beach, California (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that LENZ Therapeutics, Inc. has entered into a definitive agreement to be acquired by Amgen Inc.
Who is acquiring LENZ Therapeutics?
Amgen Inc. is acquiring LENZ Therapeutics, Inc.
What is the total value of the acquisition?
The acquisition is valued at $3.7 billion in cash.
When is the acquisition expected to be completed?
The acquisition is expected to close in the second quarter of 2025.
What is the former name of LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2025 regarding LENZ Therapeutics, Inc. (LENZ).